- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.06. | Xilio Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.05. | Xilio Therapeutics reports Q1 results | 1 | Seeking Alpha | ||
| 12.05. | Xilio Therapeutics, Inc.: Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates | 489 | GlobeNewswire (Europe) | On track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Presented new preclinical data... ► Artikel lesen | |
| 12.05. | Xilio Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 12.05. | Xilio Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.05. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 17.04. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2 | 1 | GlobeNewswire (USA) | ||
| XILIO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 16.04. | Xilio Therapeutics appoints Cheryl Blanchard to board | 1 | Investing.com | ||
| 16.04. | Xilio Therapeutics, Inc.: Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors | 1 | GlobeNewswire (USA) | ||
| 16.04. | Xilio Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.04. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 23.03. | Xilio plans mid-2026 IND filing for cancer therapy XTX501 | 2 | Investing.com | ||
| 23.03. | Xilio Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 23.03. | Xilio plant IND-Antrag für Krebstherapie XTX501 für Mitte 2026 | 2 | Investing.com Deutsch | ||
| 23.03. | Xilio Therapeutics, Inc. - 10-K, Annual Report | 3 | SEC Filings | ||
| 23.03. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results | 389 | GlobeNewswire (Europe) | XTX501, a potential best-in-class bispecific PD-1 / masked IL-2, on track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 Advancing potential first-in-class... ► Artikel lesen | |
| 23.03. | Xilio Therapeutics, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 17.03. | Xilio Therapeutics to present data on masked cancer therapy at AACR | 2 | Investing.com | ||
| 17.03. | Xilio Therapeutics, Inc.: Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 12.03. | Xilio Therapeutics implements 1-for-14 reverse stock split | 4 | Investing.com |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,324 | -0,13 % | Was Insider bei Valneva heute bereits wissen: 0,0% Plus und das könnte erst der Anfang sein - Was erfahrene Trader jetzt tun | ||
| VIVOSIM LABS | 1,120 | -0,88 % | VivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales | SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,126 | -100,00 % | Sangamo Announces Asset Sale Agreements; Commences Chapter 11 Proceedings | INDIANAPOLIS (dpa-AFX) - Sangamo Therapeutics has entered into two separate asset sale agreements, one with Eli Lilly and Company (LLY) for Sangamos capsid delivery platform, zinc finger platform... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,040 | +0,48 % | Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update | Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update
Compelling kidney function data and meta-analysis from two Phase 2 studies with varoglutamstat presented... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 15,300 | +0,92 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| VAXART | 0,380 | 0,00 % | Vaxart, Inc.: Vaxart's Two Newest Independent Directors James Breitmeyer, M.D., Ph.D., and Kevin Finney Send Letter to Shareholders Ahead of 2026 Annual Meeting | Urges Stockholders to Vote "FOR" ALL Six of Vaxart's Director Nominees on the WHITE Proxy Card TODAY Visit Vote.Vaxart.com for Additional Information and Voting Resources SOUTH SAN FRANCISCO, Calif.... ► Artikel lesen | |
| XOMA ROYALTY | 37,000 | +2,78 % | XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date | EMERYVILLE, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) ("XOMA" or the "Company") today announced that its Board of Directors has authorized the following cash... ► Artikel lesen | |
| TRAWS PHARMA | 0,870 | +3,87 % | Traws Pharma, Inc.: Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program | NEWTOWN, Pa., June 22, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, Traws, the Company), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral... ► Artikel lesen | |
| UNIQURE | 42,900 | -0,58 % | XFRA UQ1: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILUNIQURE N.V. EO... ► Artikel lesen | |
| ZAI LAB LTD ADR | 16,500 | +1,23 % | ZAI LAB (09688): NEXT DAY DISCLOSURE RETURN | ||
| TRINITY BIOTECH | 0,350 | -1,46 % | Trinity Biotech plc: Trinity Biotech Launches Trinovium to Bring Healthcare-Grade Fluid Technology to the Rapidly Growing Multi-Billion Dollar AI Data Center Liquid Cooling Market | - New subsidiary will leverage existing US and EU manufacturing capacity, high-purity fluid expertise, and analytical technologies to target liquid cooling performance and reliability in AI and high-performance... ► Artikel lesen | |
| VERASTEM | 3,557 | -3,73 % | BTIG bestätigt Kursziel von 18 $ für Verastem nach Studiendaten | ||
| VOYAGER THERAPEUTICS | 3,262 | +0,43 % | Voyager Therapeutics, Inc.: Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer's Disease | - Dosing of adults with early Alzheimer's disease in clinical trial expected H2 2026 - - Comprehensive preclinical program showed compelling pharmacology and safety profile for VY1706 - - VY1706 uses... ► Artikel lesen | |
| TVARDI THERAPEUTICS | 2,320 | +8,41 % | Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update | Topline results from healthy volunteer study and clinical development strategy for next-generation STAT3 inhibitor, TTI-109, anticipated in June Topline data from Phase 2 trial of TTI-101 in hepatocellular... ► Artikel lesen | |
| VANDA PHARMACEUTICALS | 5,120 | -1,54 % | Vanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results | Fanapt® net product sales rose 26% to $29.6 million; total prescriptions increased 32% and new-to-brand prescriptions surged 76%
NEREUS (tradipitant) launched... ► Artikel lesen |
Das Unternehmen XILIO THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 8,900 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XILIO THERAPEUTICS INC finden Sie auf Wallstreet Online.